English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background/Aims The aim of this study is to describe demographics features and outcomes of patients with rheumatic diseases diagnosed with COVID-19 in a single hospital. Methods Patients with rheumatic diseases and COVID-19 were identified via rheumatology outpatient and inpatient hospital admissions between February 2020 and March 2021. Data was collected retrospectively using the electronic medical records system and in-person and telephone consultations. The data was entered into the COVID-19 Global Rheumatology Alliance (GRA) Registry. Data collected included age, gender, ethnicity, smoker status, rheumatic disease, co-morbidities, drug history and vaccine status. Patient outcome was recorded as mortality, recovered (including days to recovery) or symptoms persisting over 90 days (&amp;gt;90). Requirement for hospital admission was also recorded. Comparison was made to the published GRA Registry data. Results Forty-three patients were identified; 33 Female (77%),10 (23%) male. Median age 52. 22 Caucasian, 12 Black, 3 mixed race, 2 Asian, 2 Hispanic and 5 unknown. Rheumatoid arthritis (14 patients; 33%) was the most common disease. Other diagnoses included psoriatic arthritis (6; 14%), systemic lupus erythematosus (4: 9%), Sjogrens syndrome (4: 9%) and ankylosing spondylitis (4; 9%). The most common disease modifying antirheumatic drug (DMARD) was methotrexate (35%) followed by hydroxychloroquine (33%). Eight patients were taking steroids (19%). Factors associated with hospitalisation were older age (57% age ≥ 52 vs 40% &amp;lt; 52), multiple co-morbidities (71% ≥ 2 co-morbidities vs 35% &amp;lt; 2 co-morbidities) and black ethnicity (75% black vs 26% of caucasian). These risk factors for morbidity are similar to the UK background population and published COVID-19 GRA data. There was no increased risk of hospitalisation between different DMARDs (53% on methotrexate required admission vs 50% on hydroxychloroquine). 71% of patients on steroids required admission. The overall study cohort had a 49% hospital admission rate. Similar risk factors were identified for persistence of symptoms &amp;gt; 90; 27% of black patients vs 5% of caucasian and 24% of patients with &amp;gt; 2 co-morbidities vs 10% of patients with &amp;lt; 2 co-morbidities. Age did not follow the same trend as hospitalisation; 10% of patients age ≥ 52 vs 20% of patients &amp;lt; 52 had symptoms &amp;gt; 90. 15% on methotrexate had a recovery time &amp;gt; 90 vs 7% on hydroxychloroquine and 14% on steroids. The overall cohort had a 17% rate of patients having symptoms &amp;gt; 90. Mortality rate within the cohort was 5% (2 patients). Conclusion A case-series of 43 patients with rheumatic diseases and COVID-19 was conducted. The risk factors for hospitalisation, mortality and persistence &amp;gt;90 were similar to other studies. Most significantly the findings show a correlation between black ethnicity and increased risk of all mortality, hospitalisation and symptoms &amp;gt; 90. There was no difference in hospitalisation and different DMARDs. Disclosure J. Pilcher: None. G. Yanni: None. P. Lutalo: None. L. Pollard: None.

rheumatology

P071 A case series of rheumatic disease patients diagnosed with COVID-19 Feb 2020 to March 2021 at the hospital that reported London’s index case of COVID-19